In our previous research, we found that subcutaneous doses of 0.83 mg/kg and 8.3 mg/kg body weight did not trigger hypercalcemia, hypercalciuria, or reduction in parathyroid hormone levels throughout their examination period [5]. The gene discussed is PTH; the disease is hypercalcemia disease.